09:55 EST AnaptysBio (ANAB) trading resumes
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio: Phase 2 rosnilimab trial did not meet primary, secondary endpoints
- AnaptysBio trading halted, news pending
- AnaptysBio’s Strategic Split and Robust Pipeline Justify Buy Rating
- AnaptysBio Reports Q3 2025 Results and Strategic Plans
- AnaptysBio’s Strategic Split and Promising Clinical Developments Drive Buy Rating